GlassScriptPhysician profile
Gretchen D Lockard
NPI 1023069796
$11,995.76
in general payments reported to CMS, 2019-2025
59 companies · $1,907 in 2025
The $1,907 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $1,325 · 2021: $1,825 · 2022: $1,628 · 2023: $1,967 · 2024: $2,290 · 2025: $1,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,059 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,059.35 |
| Education | $104.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,391.07 | 2019-2025 | |
| Novo Nordisk INC | $1,368.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,185.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,001.08 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $829.33 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $755.20 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $540.82 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $513.31 | 2019-2024 | Otezla, Repatha, Prolia |
| Allergan, INC. | $329.49 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.63 | 2021-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $234.05 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Amneal Pharmaceuticals LLC | $214.86 | 2021-2024 | Unithroid |
| Abbott Laboratories | $197.46 | 2021-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $195.37 | 2019-2025 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $191.62 | 2021 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $185.03 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $165.77 | 2020-2023 | Rexulti |
| Exact Sciences Corporation | $160.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $157.46 | 2022 | |
| Merck Sharp & Dohme LLC | $154.56 | 2019-2025 | Capvaxive, Gardasil 9 |
| Dexcom, INC. | $144.39 | 2021-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $123.20 | 2020-2025 | Nexletol |
| Daiichi Sankyo INC. | $118.90 | 2021-2024 | Injectafer |
| Astellas Pharma US INC | $116.93 | 2023-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $111.96 | 2019-2024 | |
| Amarin Pharma, INC. | $109.67 | 2020-2022 | |
| Sanofi Pasteur INC. | $103.57 | 2019-2023 | |
| Eisai INC. | $95.81 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $89.50 | 2023-2025 | Opsumit, Uptravi |
| Ardelyx, INC. | $72.12 | 2024-2025 | Ibsrela |
| Seqirus USA INC | $68.57 | 2023-2025 | Flucelvax, Fluad, Fluad Quadrivalent |
| Xeris Pharmaceuticals, INC. | $66.40 | 2021-2025 | Keveyis, Gvoke Hypopen |
| Insightec,INC | $64.28 | 2024 | Exablate |
| Bayer Healthcare Pharmaceuticals INC. | $61.95 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $58.86 | 2021-2022 | |
| Shire North American Group INC | $54.56 | 2019 | |
| Genentech USA, INC. | $49.92 | 2019-2021 | |
| Inspire Medical Systems, INC. | $35.59 | 2024 | Inspire |
| Idorsia Pharmaceuticals US INC | $35.10 | 2023 | Quviviq |
| Edwards Lifesciences Corporation | $31.77 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Impulse Dynamics (USA) INC. | $28.85 | 2023 | Optimizer |
| Tms Neurohealth Centers INC. | $28.42 | 2025 | Tms Neurohealth Centers INC. |
| Lundbeck LLC | $22.16 | 2024 | Vyepti |
| Aimmune Therapeutics, INC. | $19.82 | 2025 | Zenpep |
| Boston Scientific Corporation | $19.52 | 2022 | |
| Sumitomo Pharma America, INC. | $18.88 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $18.14 | 2022 | |
| Gilead Sciences, INC. | $17.02 | 2021 | |
| Axsome Therapeutics, INC. | $16.85 | 2025 | Symbravo |
| Philips North America LLC | $16.68 | 2024 | (Ck6) Holter |
| Kyowa Kirin, INC. | $16.55 | 2025 | |
| Exeltis, USA INC. | $16.17 | 2023 | Slynd |
| Neurelis, INC. | $16.10 | 2022 | |
| Medtronic Vascular, INC. | $15.76 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $15.65 | 2021 | |
| Upsher-Smith Laboratories LLC | $13.79 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.41 | 2022 | |
| Currax Pharmaceuticals LLC | $12.68 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gretchen Lockard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.